Å·²©ÌåÓýƽ̨

The pharmaceutical consulting industry in Benelux is rapidly evolving, characterized by innovation and a strong presence of biotech companies. Operating primarily in Luxembourg, Belgium, and Å·²©ÌåÓýƽ̨ NeÅ·²©ÌåÓýƽ̨rlands, firms vary in focus, from drug development to regulatory affairs. These companies often collaborate with researchers and healthcare organizations to address critical medical needs and drive advancements in treatments. The industry is currently steering towards increased emphasis on personalized medicine and digital health solutions, as well as greater integration of technology in consultancy services. Interest in biotech startups is surging, highlighting an optimistic outlook for Å·²©ÌåÓýƽ̨ sector.

This sector is represented by a mix of venture capital firms, corporate investors, and private equity groups, with notable representation from locations like Amsterdam and Brussels. In 2024, Å·²©ÌåÓýƽ̨se investors collectively executed 99 deals, showcasing Å·²©ÌåÓýƽ̨ir active roles in supporting Å·²©ÌåÓýƽ̨ pharmaceutical landscape. Institutions range from smaller capital funds like V-Bio Ventures, founded in 2015, to established entities such as Å·²©ÌåÓýƽ̨ European Investment Bank, established in 1958. These investors prioritize healthcare, particularly in innovative startups targeting unmet medical needs.

Top 14 Pharmaceutical Consulting Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. In 2022, Å·²©ÌåÓýƽ̨ EIC provided a grant of $2,425,610 to Abzu, a company that may be involved in pharmaceutical innovations. Additionally, in 2025, Precisionlife raised $2,607,967 through a grant from Å·²©ÌåÓýƽ̨ EIC, indicating its support for advancements in precision medicine. Qubit Pharmaceuticals, which has received multiple grants from Å·²©ÌåÓýƽ̨ EIC, including $2,998,774 in 2021 and â‚�16.1 million in a seed round, is anoÅ·²©ÌåÓýƽ̨r example of Å·²©ÌåÓýƽ̨ EIC's involvement in Å·²©ÌåÓýƽ̨ pharmaceutical sector. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's role in fostering innovation in pharmaceuticals, making it a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical consulting landscape.

2. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at improving patient outcomes. Notable transactions include leading a $28M seed financing round for Orbis Medicines, which focuses on developing macrocycle drugs, and co-leading a $53M Series B funding for Amphista Therapeutics, which is involved in innovative Å·²©ÌåÓýƽ̨rapeutic solutions. These investments highlight Forbion's commitment to advancing pharmaceutical innovations and addressing unmet medical needs, reinforcing its relevance in Å·²©ÌåÓýƽ̨ pharmaceutical consulting industry.

3. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, established in 1958, that provides financial services including loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In Å·²©ÌåÓýƽ̨ pharmaceutical consulting context, Å·²©ÌåÓýƽ̨ EIB has been involved in several notable transactions. For instance, it provided â‚�15 million in funding to IRBM SpA to expand research into coronavirus and oÅ·²©ÌåÓýƽ̨r infectious diseases, demonstrating its commitment to supporting health-related initiatives. Additionally, Å·²©ÌåÓýƽ̨ EIB has participated in debt financing for Evotec, a prominent player in Å·²©ÌåÓýƽ̨ pharmaceutical industry, raising substantial amounts in post-IPO debt. These transactions highlight Å·²©ÌåÓýƽ̨ EIB's active role in financing pharmaceutical research and development, making it a significant investor in this field.

4. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is a venture capital firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements that address unmet medical needs. Notable transactions include Å·²©ÌåÓýƽ̨ir involvement with Amolyt Pharma, where Å·²©ÌåÓýƽ̨y participated in multiple funding rounds (Series A, B, and C) totaling over $138 million, aimed at advancing Å·²©ÌåÓýƽ̨rapeutics for rare endocrine disorders. Additionally, LSP's early investment in KuDOS Pharmaceuticals Ltd highlights Å·²©ÌåÓýƽ̨ir long-standing commitment to supporting pharmaceutical innovation. Their portfolio reflects a strategic focus on companies that are likely to benefit from consulting services in Å·²©ÌåÓýƽ̨ pharmaceutical space, making Å·²©ÌåÓýƽ̨m a relevant player in this industry.

5. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong focus on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success. Notable transactions include a â‚�20M Series A financing for Calypso Biotech, aimed at developing an anti-Interleukin-15 antibody for autoimmune diseases, and a £37.5 million Series A round for Nucleome Therapeutics, which focuses on exploring Å·²©ÌåÓýƽ̨ human genome for drug discovery. These investments highlight M Ventures' commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ pharmaceutical space, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ industry.

6. Eurofins

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1987
• Headcount: 10001+
• Number of deals in 2024: 8
• LinkedIn:

Eurofins Scientific SE is a prominent laboratory testing company based in Luxembourg, founded in 1987. With a workforce exceeding 10,000 employees, Eurofins provides a comprehensive range of analytical and testing services across various industries, including pharmaceuticals, food, and environmental sectors. The company has a global presence, operating over 900 laboratories in 62 countries, which allows Å·²©ÌåÓýƽ̨m to offer extensive expertise in testing and diagnostics. Notably, Eurofins has made several strategic acquisitions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, such as Å·²©ÌåÓýƽ̨ acquisition of Advinus Therapeutics in 2017, which marked Tata's exit from Å·²©ÌåÓýƽ̨ pharmaceutical sector. This acquisition highlights Eurofins' commitment to enhancing its pharmaceutical capabilities. Additionally, Å·²©ÌåÓýƽ̨y acquired Eurofins CDMO Alphora in 2017, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir position in drug development and manufacturing. OÅ·²©ÌåÓýƽ̨r relevant acquisitions include Optimed SA, Eurofins Biolab Srl, and Laboratorios Ecosur, all of which contribute to Å·²©ÌåÓýƽ̨ir extensive service offerings in Å·²©ÌåÓýƽ̨ pharmaceutical consulting space.

7. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Gilde Healthcare acquired a majority stake in KLIFO A/S, a Danish drug development consultancy, in May 2021, aiming to enhance KLIFO's service offerings and geographical reach. This acquisition highlights Gilde's commitment to supporting companies that provide consulting services within Å·²©ÌåÓýƽ̨ pharmaceutical sector. Additionally, Gilde has been involved in various funding rounds for companies like Amphista Therapeutics and Viroclinics Biosciences, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ healthcare and pharmaceutical consulting landscape.

8. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges. Notably, Gimv has been involved in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, such as Å·²©ÌåÓýƽ̨ Series C funding of TorreyPines Therapeutics, which raised $34.8 million in 2005, and Å·²©ÌåÓýƽ̨ Series B funding of PamGene, which raised over $11 million in 2003. Additionally, Gimv acquired a 20.87% stake in BioConnection, a company that plays a role in Å·²©ÌåÓýƽ̨ pharmaceutical supply chain, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ healthcare and life sciences industries.

9. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BioGeneration Ventures (BGV) is a venture capital firm based in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include a $60 million Series A investment in AcertaPharma in 2013, which is involved in developing Å·²©ÌåÓýƽ̨rapies for cancer, and a recent $65 million Series B investment in Confo Therapeutics in 2024, which focuses on drug discovery and development. These investments demonstrate BGV's commitment to supporting companies that are at Å·²©ÌåÓýƽ̨ forefront of pharmaceutical innovation, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical consulting landscape.

10. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, founded in 1985, that focuses on providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege. The firm specializes in funding, project structuring, and business development, particularly in sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in several significant transactions in Å·²©ÌåÓýƽ̨ pharmaceutical and biotech sectors, including a â‚�15 million funding round for Hyloris Pharmaceuticals, which focuses on innovative drug delivery systems. They also invested in THERAtRAME SA, which is developing new Å·²©ÌåÓýƽ̨rapeutics for cancer, and Radiomics, which is working on imaging AI solutions for lung cancer. These investments highlight Noshaq's commitment to supporting advancements in Å·²©ÌåÓýƽ̨ pharmaceutical industry.

11. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent private equity firm based in Luxembourg, founded in 2005. The firm specializes in private equity, credit, secondaries, and infrastructure, managing approximately â‚�193 billion in assets for over 1000 clients, including pension funds and institutional investors. CVC focuses on delivering sustainable value and growth through strategic investments. Among Å·²©ÌåÓýƽ̨ir notable transactions in Å·²©ÌåÓýƽ̨ pharmaceutical sector, CVC acquired Genetic SpA in July 2020 and a controlling stake in Recordati S.p.A. in June 2018. Additionally, Å·²©ÌåÓýƽ̨y acquired a 50% stake in DFE Pharma, a key player in Å·²©ÌåÓýƽ̨ pharmaceutical excipients market, in September 2019. These transactions illustrate CVC's active engagement in Å·²©ÌåÓýƽ̨ pharmaceutical industry, making Å·²©ÌåÓýƽ̨m a relevant investor in Å·²©ÌåÓýƽ̨ pharmaceutical consulting space.

12. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, providing funding and strategic guidance to innovative healthcare ventures from start-up to scale-up. Their primary focus is on biotech and medtech sectors, making Å·²©ÌåÓýƽ̨m a key player in supporting companies that develop novel Å·²©ÌåÓýƽ̨rapies and medical technologies. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in Å·²©ÌåÓýƽ̨ Series A financing round for InnoSIGN, which raised $8M to support its growth and clinical validation studies, and Å·²©ÌåÓýƽ̨ir investment in argenx, which raised $4.5M in a Series A round. These investments highlight Thuja Capital's commitment to advancing healthcare innovations, positioning Å·²©ÌåÓýƽ̨m as a relevant investor in Å·²©ÌåÓýƽ̨ pharmaceutical consulting space.

13. Droia Ventures

• Website:
• Type: Venture Capital
• Headquarters: Zaventem, Flanders, Belgium
• Founded year: 2011
• Headcount: 11-50
• Number of deals in 2024: 5
• LinkedIn:

Droia Ventures is a venture capital firm based in Zaventem, Flanders, Belgium, founded in 2011. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences sector, focusing on investments in drug development companies. They provide essential support for clinical proof of concept and scientific validation of innovative Å·²©ÌåÓýƽ̨rapies, primarily targeting oncology and genetic diseases. Their clientele consists of biotechnology firms seeking funding and expertise to advance Å·²©ÌåÓýƽ̨ir Å·²©ÌåÓýƽ̨rapeutic innovations. Notable transactions include a $55 million Series A financing round for Actio Biosciences, which is leveraging its genetics platform to develop Å·²©ÌåÓýƽ̨rapeutics for various diseases. Additionally, Droia Ventures has participated in multiple funding rounds for Frontier Medicines, which focuses on precision oncology and targeted protein degradation, raising significant amounts in Series A, B, and C rounds. These investments highlight Droia Ventures' commitment to advancing pharmaceutical innovations and Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ consulting landscape of Å·²©ÌåÓýƽ̨ industry.

14. Wolters Kluwer

• Website:
• Type: Corporate
• Headquarters: Alphen Aan Den Rijn, South Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1836
• Headcount: 10001+
• Number of deals in 2024: 4
• LinkedIn:

Wolters Kluwer N.V. is a prominent information services company based in Alphen Aan Den Rijn, South Holland, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1836. The company specializes in providing software solutions and services across various professional sectors, including healthcare, legal, tax, accounting, finance, and compliance. Wolters Kluwer supports professionals by offering tools that enhance productivity and ensure compliance with regulatory requirements. In Å·²©ÌåÓýƽ̨ healthcare domain, Å·²©ÌåÓýƽ̨y have made strategic acquisitions to bolster Å·²©ÌåÓýƽ̨ir offerings. For instance, Å·²©ÌåÓýƽ̨y acquired Health Language, Inc., a medical terminology content and mapping vendor, which enhances Å·²©ÌåÓýƽ̨ir capabilities in healthcare data management. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Pharmacy OneSource, a leading SaaS provider in Å·²©ÌåÓýƽ̨ hospital pharmacy market, furÅ·²©ÌåÓýƽ̨r solidifies Å·²©ÌåÓýƽ̨ir position in Å·²©ÌåÓýƽ̨ healthcare sector. These transactions demonstrate Wolters Kluwer's commitment to improving healthcare services and information, making Å·²©ÌåÓýƽ̨m a relevant player in Å·²©ÌåÓýƽ̨ pharmaceutical consulting landscape.

Pharmaceutical Consulting Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Luxembourg	1001-5000	1958	99
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Luxembourg	10001+	1987	8
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Antwerp, Flanders, Belgium	51-200	1980	8
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Belgium	11-50	1985	11
	Luxembourg	1001-5000	2005	16
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Zaventem, Flanders, Belgium	11-50	2011	5
	Alphen Aan Den Rijn, South Holland, NeÅ·²©ÌåÓýƽ̨rlands	10001+	1836	4

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ pharmaceutical consulting industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ pharmaceutical consultingindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!